The Nasdaq has been absolutely obliterated this year, down a stunning 27%, which puts the tech-heavy index firmly in bear market territory. One of the biggest reasons for this is the large tech influence of the index, but another is that many stocks were horribly overbought and have been pushed to absurd levels by the FOMO, or “fear of missing out,” group.

There has been a glimmer of hope on the horizon for stock investors recently. While the all-clear rally flag is not being waved, it does appear that some of the worst is behind us. The consumer and producer price index numbers for October seem to indicate that we may have hit peak inflation and it is starting to come down. If that is indeed the case, brighter days may be ahead.

While many feel that the recent rally is of the bear market variety, the potential for the Santa Claus rally, which tends to be the ultimate seasonality play, means investors might be able to make some hay while the sun shines for the balance of 2022.

Given the Nasdaq’s awful year we decided to screen the index looking for the highest-yielding stocks and found that they all have some solid defensive qualities and are offering among the best entry points in some time.

Stocks are listed in order of the highest yield.

Intel

This legacy leader in semiconductors has been hammered, and while some feel it is a value trap, it is hard to count out the company that defined the semiconductor revolution. Intel Corp. (NASDAQ: INTC) designs, manufactures and sells integrated digital technology platforms worldwide.

The platforms are used in various computing applications, comprising notebooks, two-in-one systems, desktops, servers, tablets, smartphones, wireless and wired connectivity products, wearables, retail devices and manufacturing devices, as well as for retail, transportation, industrial, buildings, home use and other market segments.

Intel announced last January it would invest significantly to build potentially the world’s largest chip-making complex in Ohio, looking to boost capacity as a global shortage of semiconductors affects everything from smartphones to automobiles. Intel says the 1,000-acre “mega-site” northeast of Columbus has room for as many as eight plants, known as “fabs.” The company estimates it would require a $100-billion investment to fully build and equip those plants.

Shareholders receive a 4.92% dividend. Needham has a $32 price target on Intel stock. The consensus target is $31.58, and Friday’s closing share price was $27.89.

This huge drugstore chain operator is a safe retail play for investors looking to add health care now. Walgreens Boots Alliance Inc. (NASDAQ: WBA) operates as a pharmacy-led health and beauty retail company. It operates through three segments.

The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services; this segment operates nearly 10,000 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies.

The Retail Pharmacy International segment sells prescription drugs and health and wellness, beauty, personal care and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as online and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides and Ahumada in the United Kingdom, Thailand, Norway, the Netherlands, Mexico and elsewhere, and 550 optical practices, including 165 on a franchise basis.

The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home health care supplies and equipment, as well as provides related services to pharmacies and other health care providers.

Walgreens Boots Alliance stock investors receive a 4.60% dividend. Cowen’s $54 target price is well above the $41.85 consensus target and Friday’s closing price of $47.80 a share.

Kraft Heinz

Even in bad times, everybody has to eat, and this company always stands to benefit. Kraft Heinz Co. (NASDAQ: KHC) was formed via the merger of H.J. Heinz and Kraft Foods. The company is a leading global food company, with $29 billion in annual revenues generated by such well-known brands as Kraft, Heinz, Oscar Meyer and Maxwell House. Legendary investor Warren Buffett holds a big position in the stock at Berkshire Hathaway.

It is the third-largest food and beverage manufacturer in North America, deriving 76% of revenues from that market and 24% internationally. Additional brands include Oscar Meyer, Maxwell House, Capri Sun, Classico, Jell-O, Kool-Aid, Lunchables, Ore-Ida, Oscar Mayer, Philadelphia, Planters, Plasmon, Quero, Weight Watchers Smart Ones and Velveeta.

Shareholders receive a 4.11% dividend. Kraft Heinz stock is on the BofA Securities US 1 list of top picks. The firm’s price target is $48, while the $42.01 consensus target is closer to the latest close at $40.74.

This industry-leading utility is also a solid dividend-paying company. American Electric Power Co. Inc. (NYSE: AEP) is one of the largest electric utilities in the United States, delivering electricity to more than 5.4 million customers in 11 states.

The company ranks among the nation’s largest generators of electricity, owning nearly 38,000 megawatts of generating capacity in the United States. It also owns the nation’s largest electricity transmission system, a more than 40,000-mile network that includes more 765-kilovolt extra-high voltage transmission lines than all other U.S. transmission systems combined.

Many on Wall Street feel that the stock trades at a discount to its utility peers, and they feel it deserves a premium. Top analysts also think the company may sell generating assets and buy back shares with the proceeds, which also will be accretive.

Shareholders receive a 3.49% dividend. Morgan Stanley analysts have set a $111 price target. The consensus target for American Electric Power stock is $107.88, and shares closed on Friday at $88.83.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Gilead Sciences

This stock is trading at a reasonable 12 times estimated 2022 earnings and has big-time upside potential. Gilead Sciences Inc. (NASDAQ: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in the areas of unmet medical need in the United States, Europe and elsewhere.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy and Zydelig products for the treatment of hematology, oncology and cell therapy patients.

In addition, Gilead provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

The company has collaboration agreements with Arcus Biosciences, Pionyr, Tizona, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Merck and Novo Nordisk.

The dividend yield is 3.43%. The $100 Argus price objective is the highest on Wall Street. The consensus target is $81.75, but Gilead Sciences stock ended last week trading at $86.26 a share.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.